Ahmedabad-based Indo US Bio-Tech Limited has unveiled a comprehensive agricultural innovation roadmap, allocating ₹71.51 crore to research, infrastructure, and export initiatives by 2030-31, as per PTI report.
The company will invest ₹25 crore in a 100-acre R&D facility, including a ₹5 crore high-tech greenhouse and ₹75 lakh net house. A 5,000 sq ft seed processing plant will be established with ₹75 lakh for infrastructure and ₹1.25 crore for machinery.
Indo US Bio-Tech targets international growth with ₹5.70 crore for US market entry (projected 12% annual growth, ₹10 crore revenue by 2027-28) and ₹5.60 crore for African markets (Kenya, Nigeria, Ghana; 15% growth, ₹8 crore revenue target). Total export investment: ₹11.30 crore.
A ₹15 crore joint venture (50% equity) will establish a groundnut seed processing and packaging plant, contributing to a total 2026-27 investment of ₹59.55 crore.
A five-year, ₹5 crore initiative aims to develop disease-resistant tomato varieties. Phased investments include lab setup (₹50 lakh), breeding/trials (₹75 lakh), molecular studies (₹1 crore), large-scale trials (₹1.25 crore), and market launch (₹1.50 crore). Expected outcomes: 2-3 resistant varieties, 25-40% yield loss reduction.
Read More: Zydus Lifesciences’ Share Price in Focus; Ahmedabad Injectable Facility Clears USFDA Inspection!
Bottle gourd development (₹1.25 crore) focuses on lab setup, hybridization, and trials. Chilli R&D (₹2.15 crore) involves germplasm collection, cross-breeding, and pre-commercial launches. Both projects target high-yield, disease-resistant hybrids.
A ₹5 crore upgrade includes advanced machinery, sorting systems, and facility expansion to boost production capacity and efficiency.
Brinjal R&D (₹2.65 crore) targets bacterial wilt/Phomopsis blight resistance, aiming for 50-60% yield improvement. Tomato seed innovation (₹2.69 crore) focuses on nutrient extraction and sustainable agriculture over two years.
As of February 23, 2026, at 10:09 AM, Indo Us Bio-Tech share price on NSE was trading at ₹151.03 up by 0.21% from the previous closing price.
Indo US Bio-Tech's ₹71.51 crore roadmap emphasizes disease-resistant crop development and global market penetration. With projected revenue growth and potential 70% profit margins, the initiative positions the company for leadership in agricultural innovation and export-driven expansion by 2031.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 23, 2026, 11:23 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
